| 6.945 -0.185 (-2.59%) | 01-14 11:20 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.6 | 1-year : | 10.05 |
| Resists | First : | 7.36 | Second : | 8.6 |
| Pivot price | 6.35  |
|||
| Supports | First : | 6.15 | Second : | 5.4 |
| MAs | MA(5) : | 7.09 |
MA(20) : | 6.33 |
| MA(100) : | 7.5 |
MA(250) : | 10.92 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.6 |
D(3) : | 87.9 |
| RSI | RSI(14): 57.8 |
|||
| 52-week | High : | 28 | Low : | 5.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SENS ] has closed below upper band by 26.5%. Bollinger Bands are 36.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.31 - 7.34 | 7.34 - 7.36 |
| Low: | 6.95 - 6.99 | 6.99 - 7.02 |
| Close: | 7.07 - 7.13 | 7.13 - 7.18 |
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Tue, 13 Jan 2026
Senseonics Holdings, Inc.'s (NASDAQ:SENS) Share Price Could Signal Some Risk - simplywall.st
Mon, 12 Jan 2026
SENS Anticipates Strong Growth in 2026 with Key Developments - GuruFocus
Mon, 12 Jan 2026
Senseonics (SENS) Projects Strong Revenue Growth for 2026 - GuruFocus
Mon, 12 Jan 2026
Diabetes implant maker sees 71% sales jump as year-long glucose monitor grows - Stock Titan
Fri, 09 Jan 2026
SENS Stock Up as Eversense 365 Enters AID Market With twiist System - Yahoo Finance
Fri, 09 Jan 2026
SENS Shares Surge After First Commercial Patients Use AID-Integrated Continuous Glucose Monitor System - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|